logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience cites FDA statement on nicotine replacement therapy to help smokers quit

FDA Commissioner Scott Gottlieb said nicotine replacement therapy is 'generally considered to double the likelihood of a successful quit attempt'

Lexaria tablets
The firm is working with a 'world-leading tobacco company' on ingestible nicotine

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) cited on Tuesday a Food and Drug Administration statement on the development of safe and effective nicotine replacement therapies to help smokers quit cigarettes.

The Kelowna, British Columbia-based firm said it was working with a "world-leading tobacco company" to develop ingestible delivery of nicotine.

Positive results of this research and development program could provide nicotine products that meet the goals of the FDA, Lexaria said in a statement Tuesday. The company added that it will earn royalties on products sold by its tobacco partner that use its DehydraTECH delivery technology.

READ: Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products

FDA Commissioner Scott Gottlieb said in a February 21 statement cited by Lexaria that nicotine replacement therapy is generally considered "to double the likelihood of a successful quit attempt.”

Lexaria said its technology could offer a method of delivering nicotine that preserves consumer choice, avoids the most serious health consequences of smoking cigarettes and harmonizes with current FDA policies.

The technology, according to the company, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

In January, a unit of Lexaria entered into a definitive agreement with Altria Group Inc (NYSE:MO) to fund the research and development of Lexaria's patented DehydraTECH technology.

Shares of Lexaria rose 1.7% to C$1.84 in Monday’s Canadian trading. They climbed 2.2% to US$1.41 on the OTC Markets.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Lexaria Bioscience Corp.

Price: 0.63 CAD

CSE:LXX
Market: CSE
Market Cap: $50.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

on 22/1/20

2 min read